Alexander N. Shoushtari, MD

Alexander N. Shoushtari, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.

Alexander N. Shoushtari, MD, discusses the design of the ​phase 3 CheckMate-067 trial in advanced melanoma. 

Alexander N. Shoushtari, MD, discusses the role of nivolumab and ipilimumab in mucosal melanoma. 

Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.